Ximbio, the world's largest non-profit organisation dedicated to life science research reagents, is pleased to announce a new partnership with the Medical Research Council (MRC). LifeArc has facilitated this agreement and will be managing the collaboration on behalf of MRC.
”Ximbio’s global network, capabilities and values makes it a natural partner to provide access to MRC reagents. This partnership will provide researchers with easier access to valuable research tools that could help to maximize its impact in life science research and development.” said Dr Rob Buckle, Chief Science Officer, MRC
This arrangement will utilise Ximbio’s capabilities to produce bulk quantities of the MRC’s large portfolio of antibodies. It will also allow Ximbio to distribute a selection of MRC cell line models via its global platform to both academic and commercial life science researchers—potentially enabling more research professionals to benefit from these valuable tools. The MRC catalogue comprises more than 100 hybridomas developed by MRC researchers, many of them in collaboration with other academic partners.
“We are delighted to partner with the MRC. Research tools play a huge role in achieving scientific breakthroughs but are often overlooked. Through this partnership, we will be able to support the goal of the MRC to accelerate life science research,” said Robert Bondaryk, Global Head, Ximbio.
Discover how you could benefit from a partnership with Ximbio
Notes to Editors
Ximbio is the world’s largest non-profit dedicated to life science research reagents of all kinds. Its mission is to make life science research reagents widely and easily available to you and other scientists to accelerate life science research. It is part of Cancer Research UK, the largest independent funder of cancer research in the world. Any profit generated by Ximbio is used to support Cancer Research UK’s work.
For more information on Ximbio or this article, please contact Emma Fisher at firstname.lastname@example.org.
About the Medical Research Council
The Medical Research Council (MRC) improves the health of people in the UK - and around the world - by supporting excellent science and training the very best scientists. The MRC is part of UK Research and Innovation.
For more information on MRC or this article please contact email@example.com
LifeArc is a self-funded medical research charity. Our mission is to advance translation of early science into health care treatments or diagnostics that can be taken through to full development and made available to patients. We have been doing this for more than 25 years and our work has resulted in a diagnostic for antibiotic resistance and four licensed medicines.
Our success allows us to explore new approaches to stimulate and fund translation. We have our own drug discovery and diagnostics development facilities, supported by experts in technology transfer and intellectual property who also provide services to other organisations. Our model is built on collaboration, and we partner with a broad range of groups including medical research charities, research organisations, industry and academic scientists. We are motivated by patient need and scientific opportunity.
Two funds help us to invest in external projects for the benefit of patients: our Philanthropic Fund provides grants to support medical research projects focused on the translation of rare diseases research and our Seed Fund is aimed at start-up companies focussed on developing new therapeutics and biological modalities. Find out more about our work on www.lifearc.org or follow us on LinkedIn or Twitter.